Engaging Innovation | Friends of Cancer Research

Engaging Innovation

Featured Post

December 10, 2018

Friends of Cancer Research Annual Meeting 2018

This year’s Friends of Cancer Research (Friends) Annual Meeting started with a morning keynote by Anna Abram the Deputy Commissioner for Policy, Planning, Legislation and Analysis at the U.S. Food and Drug Administration (FDA). Abram discussed many different initiatives that have been led by Friends over the years including the...
More Posts

Recent Posts

No Results With Current Filter Choices

A Blueprint for Breakthrough: Research and Reimbursement in the Age of Precision Medicine

  Next-generation sequencing (NGS) is becoming a commonly used tool in cancer treatment. Transparency regarding the clinical performance and utility of different NGS-based tests available will aid in clinical decision-making and facilitate improvements in patient care.  The 7th Annual Blueprint for Breakthrough Forum, held by Friends of Cancer Research (Friends) and...

The Future Use of Real-World Evidence

  Significant progress has been made in data collection efforts to support use of real-world evidence (RWE) in regulatory settings; however challenges remain, chiefly with combining, organizing, and analyzing data from various information sources. On July 10th, Friends of Cancer Research (Friends) hosted a meeting to present data from a pilot...

A Plea to Make Cancer Clinical Trials More Patient Friendly

Jim Omel is a myeloma patient and a cancer research advocate. He spoke at the 2017 Friends of Cancer Research Annual Meeting and was an author of the panel 2 whitepaper, Data Generation to Support Cross-Labeling of Indications for Combination Products. Below are his abridged remarks from the meeting. To...

Biopharma Congress III

November 14, 2017Disruption In BiopharmaThe Ritz-Carlton, Washington D.C.1150 22nd Street, NW On Tuesday, November 14, 2017, Friends of Cancer Research (Friends) and Prevision Policy hosted the third annual BioPharma Congress. This year’s event focused on disruption in biopharma and featured speakers such as former FDA Commissioner Dr. Mark McClellan and former...

Friends of Cancer Research Annual Meeting 2017

Panel 1 Whitepaper - Panel 1 Slides Panel 2 Whitepaper - Panel 2 Slides Panel 3 Whitepaper - Panel 3 Slides   This year’s Friends Annual Meeting took place on November 15, 2017. The event began with a keynote by FDA Commissioner Dr. Scott Gottlieb. During his remarks, Dr. Gottlieb reiterated previous commitments for...

A Blueprint for Breakthrough – Charting the Course for Precision Medicine

Friends of Cancer Research with Alexandria Real Estate Equities, Inc. Co-Host: A Blueprint for Breakthrough – Charting the Course for Precision Medicine Click HERE to access the finalized meeting whitepaper. On Wednesday, September 13, 2017, Friends of Cancer Research (Friends) with Alexandria Real Estate Equities Inc. co-hosted the 6th annual Blueprint for...

What Is ‘Regulatory Science’ and Why Is It Here to Stay?

Regulatory science is new to the research lexicon. When Dr. Ira Shoulson began his career as a neurologist, he knew he wanted to focus on the clinical development of experiment therapeutics for neurodegenerative diseases. For nearly 30 years, Ira has been an integral leader in the design of large international,...
first
prev
1
2
next
last
Back to Top